Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 2/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23546207 | 0.86 | KDM4E (0.44) | TNFADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL20252481 | 0.85 | TNF (0.46) | TNFADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL14893767 | 0.85 | TNF (0.46) | TNFADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL14896388 | 0.85 | TNF (0.46) | TNFADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL20252484 | 0.85 | TNF (0.46) | TNFADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL28778068 | 0.85 | TNF (0.46) | TNFADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL14893930 | 0.85 | TNF (0.46) | TNFADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL20256465 | 0.85 | TNF (0.46) | TNFADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL2607319 | 0.85 | LMNA (0.53) | ADRA2AADRA2BADRA2CADRA1AADRA1D | |
| Hydrochloric Acid SCHEMBL20238239 | 0.84 | TNF (0.45) | TNFADRA2AADRA2BADRA2CADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | REMIX THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| WO-2024108155-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230365526-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023220741-A1 | ALPHA 4 BETA 7 INTEGRIN MODULATORS AND USES THEREOF | DICE MOLECULES SV, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | DISC MEDICINE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20100076020-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100056588-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2010-03-04 | — | — | US | disclosed |
| US-20100056588-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2010-03-04 | — | — | US | disclosed |
| US-20090312363-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-12-17 | — | — | US | disclosed |
| US-20090286829-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286829-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | ASTRAZENECA AB (SE) | 2009-07-16 | — | — | US | disclosed |
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | ASTRAZENECA AB (SE) | 2009-07-16 | — | — | US | disclosed |
| WO-2008136815-A2 | 5, 6-RING ANNULATED INDOLE DERIVATIVES AND USE THEREOF | SCHERING CORPORATION (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008082484-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | RBM17, HNRNPA1, HNRNPAB | TNF 4662/4885ADRA2A 2678/4885ADRA2B 2594/4885 |
| US-20100076020-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | TUBB3, TUBB1, NQO2 | TNF 2586/4885ADRA2A 1868/4885ADRA2B 2100/4885 |
| US-20090312363-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC2 | TNF 2213/4885ADRA2A 4847/4885ADRA2B 4845/4885 |
| US-20090286829-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ADRA2C, ADRA2B, ADRB3 | TNF 4686/4885ADRA2A 5/4885ADRA2B 2/4885 |
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNA2, CNR2 | TNF 4462/4885ADRA2A 128/4885ADRA2B 361/4885 |
| US-20230365526-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, RBM17, SNRPB2 | TNF 4787/4885ADRA2A 3387/4885ADRA2B 3043/4885 |
| US-20100056588-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | TNF 682/4885ADRA2A 4216/4885ADRA2B 4256/4885 |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | HNRNPAB, HNRNPC, HNRNPA1 | TNF 4018/4885ADRA2A 3589/4885ADRA2B 2774/4885 |
| US-11827662-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | TNF 4462/4885ADRA2A 3317/4885ADRA2B 2913/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | TNF 4747/4885ADRA2A 4613/4885ADRA2B 4231/4885 |
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | GFPT1, MPST, XPNPEP1 | TNF 4675/4885ADRA2A 4630/4885ADRA2B 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.